Age-stratified phase i trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 5, 2012, Pages 1117-1126

  Falchook, G S ^a   Duvic, M ^b   Hong, D S ^a   Wheler, J ^a   Naing, A ^a   Lim, J ^a   Kurzrock, R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Texas Health Science Center at Houston   (United States)

Author keywords

Bortezomib; Cutaneous T cell lymphoma; Gemcitabine; Liposomal doxorubicin; Phase I; Small cell carcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; BORTEZOMIB; DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DEOXYCYTIDINE; DRUG DERIVATIVE; PYRAZINE DERIVATIVE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGE; AGED; ANEMIA; APPENDIX CARCINOMA; ARTICLE; B CELL LYMPHOMA; BLADDER CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CHILD; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FATIGUE; FEMALE; FOOT DISEASE; GASTROINTESTINAL HEMORRHAGE; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; INFECTION; KIDNEY CANCER; LOWER ABDOMINAL PAIN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NASOPHARYNX CARCINOMA; NAUSEA; NEUROECTODERM TUMOR; NEUROENDOCRINE TUMOR; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PANCREAS ADENOCARCINOMA; PARALLEL DESIGN; PELVIS CANCER; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RECOMMENDED DRUG DOSE; SARCOMA; SIDE EFFECT; SKIN BLEEDING; SKIN DEFECT; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; T CELL LYMPHOMA; THORAX PAIN; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT RESPONSE; URINARY TRACT INFECTION; UROSEPSIS; UTERINE CERVIX CANCER; CLINICAL TRIAL; DOSE RESPONSE; DRUG POTENTIATION; MIDDLE AGED; NEOPLASM; PATHOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CHILD; CHILD, PRESCHOOL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PYRAZINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862281935     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1808-4     Document Type: Article

References (24)

1. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108-2121 (Pubitemid 41095144)
2. Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM (2005) Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol 23:6107-6116
3. Heinz-Josef L (2003) Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 29:41-48
4. Paramore A, Frantz S (2003) Bortezomib. Nat Rev Drug Discov 2:611-612
5. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2′, 2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110-6117
6. Plunkett W, Huang P, Gandhi V (1995) Preclinical characteristics of gemcitabine. Anticancer Drugs 6(Suppl 6):7-13 (Pubitemid 26014890)
7. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3-10
8. Risbood PA, Kane CT Jr, Hossain MT, Vadapalli S, Chadda SK (2008) Synthesis of gemcitabine triphosphate (dFdCTP) as a tris(triethylammonium) salt. Bioorg Med Chem Lett 18:2957-2958 (Pubitemid 351622041)
9. Siegal T, Horowitz A, Gabizon A (1995) Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg 83:1029-1037 (Pubitemid 26048143)
10. Rivera E, Valero V, Syrewicz L, Rahman Z, Esteva FJ, Theriault RL, Rosales MM, Booser D, Murray JL, Bast RC Jr, Hortobagyi GN (2001) Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol 19:1716-1722 (Pubitemid 32230872)
11. Gabizon A, Shmeeda H, Barenholz Y (2003) Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 42:419-436 (Pubitemid 36649037)
12. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101:2377-2380 (Pubitemid 36302084)
13. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, McConkey DJ (2004) The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 3:279-290 (Pubitemid 39193703)
14. Ryan DP, Appleman LJ, Lynch T, Supko JG, Fidias P, Clark JW, Fishman M, Zhu AX, Enzinger PC, Kashala O, Cusack J Jr, Eder JP (2006) Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer 107:2482-2489 (Pubitemid 44748533)
15. CW LuuT, Lim D et al (2010) Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors. Anticancer Res 30:167-174
16. Dees EC, O'Neil BH, Lindley CM, Collichio F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D, Orlowski RZ (2008) A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Cancer Chemother Pharmacol 63:99-107
17. Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL III, Pusztai L, Hortobagyi GN (2003) Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 21:3249-3254 (Pubitemid 46606257)
18. Mortenson MM, Schlieman MG, Virudachalam S, Lara PN, Gandara DG, Davies AM, Bold RJ (2005) Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer. Lung Cancer 49:163-170 (Pubitemid 40966743)
19. Davies AM, Lara PN Jr, Mack PC, Gandara DR (2007) Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res 13:s4647-s4651
20. Walenkamp AM, Sonke GS, Sleijfer DT (2009) Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev 35:228-236
21. Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, Wood WC, Henderson IC, Hudis C, Winer E, Cohen H, Wheeler J, Norton L (2005) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073-1081 (Pubitemid 40300281)
22. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091-1097
23. O'Malley K, Crooks J, Duke E, Stevenson IH (1971) Effect of age and sex on human drug metabolism. Br Med J 3:607-609
24. Lipshitz DA, Goldstein S, Reis R et al (1985) Cancer in the elderly: basic science and clinical aspects. Ann Intern Med 102:218-228 (Pubitemid 15157177)